CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980

Απλή σελίδα τεκμηρίου
dc.contributor.authorKunschner, L. J.en
dc.contributor.authorFine, H.en
dc.contributor.authorHess, K.en
dc.contributor.authorJaeckle, K.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T19:30:32Z
dc.date.available2015-11-24T19:30:32Z
dc.identifier.issn0735-7907-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23116
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useen
dc.subjectBrain Neoplasms/*drug therapyen
dc.subjectCarbamates/administration & dosage/adverse effects/*therapeutic useen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectGlioma/*drug therapyen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapyen
dc.subjectPyrazines/administration & dosage/adverse effects/*therapeutic useen
dc.subjectPyridines/administration & dosage/adverse effects/*therapeutic useen
dc.subjectSurvival Rateen
dc.subjectThrombocytopenia/chemically induceden
dc.subjectTreatment Outcomeen
dc.titleCI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980en
heal.abstractOBJECTIVE: The purpose of this phase I/II trial was to determine the maximal tolerated dose of CI-980, and determine efficacy against malignant glioma. BACKGROUND: The CI-980 is a synthetic mitosis inhibitor that acts via the colchicine binding site on tubulin. Broad in vitro activity has been seen in a variety of human and murine tumor models. Phase I studies have demonstrated schedule dependent toxicity of CI-980. Dose-limiting toxicity was neurologic when CI-980 was given as a 24-hr infusion and hematologic when given over 72 hr at higher doses. METHODS: Twenty-four patients ages 29-65 entered this study. Six patients were treated on the phase I arm at three escalating dose levels ranging from 10.5 to 13.5 mg/m2, given over 72 hr. Eighteen patients were then treated at the highest tolerated dose, 13.5 mg/m2 per cycle. Treatment response was based on serial MRI imaging characteristics. RESULTS: The phase II study was stopped at the end of the first stage due to poor treatment response. There were no partial or complete responses, (0/24) 95% CI = 0-14%. Four patients (4/24) had a best treatment response of stable disease/no change. Median time to progression for all patients was 6.4 weeks (95% CI: 6-9 weeks). Dose-limiting toxicity was grade 3-4 granulocytopenia. Three episodes of neurotoxicity manifested by a moderate cerebellar dysfunction were seen. CONCLUSIONS: These results fail to demonstrate the significant activity of CI-980 against recurrent glioma.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12449727-
heal.journalNameCancer Investen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2002-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ